PE Rabbit anti-Human CD303/BDCA-2 Monoclonal Antibody for FC - Q8WTT0

Core Product Specifications and Parameters

Biological Background: CD303/BDCA-2 (CLEC4C) Function and Localization

• CD303/BDCA-2, encoded by the CLEC4C gene, is a C-type lectin receptor also known as blood dendritic cell antigen 2. It is a type II transmembrane glycoprotein belonging to the C-type lectin family.
• As a cell surface receptor on plasmacytoid dendritic cells, CD303/BDCA-2 specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the Gal(beta1-3/4)GlcNAc(beta1-2)Man epitope and binds to serum IgG. This interaction facilitates antigen capture and presentation to T cells, linking innate and adaptive immunity. Related references: PMID:11748283 PMID:21880719 PMID:25995448
• Upon ligand binding, CD303/BDCA-2 activates protein-tyrosine kinases, mobilizes intracellular calcium, and mediates potent inhibition of interferon-alpha/beta induction in plasmacytoid dendritic cells. Related references: PMID:11748283 PMID:21880719
• The receptor is localized to the cell membrane and is constitutively expressed in immature monocyte-derived dendritic cells and plasmacytoid dendritic cells. Its surface expression is down-regulated upon LPS-induced maturation but not by TNF treatment.
• Structurally, the protein contains a C-type lectin domain, disulfide bonds, and a metal-binding site. It undergoes glycosylation and alternative splicing, contributing to its functional diversity.
• CD303/BDCA-2 plays a dual role in immunity: it captures antigens for T-cell presentation while simultaneously suppressing type I interferon responses, highlighting its regulatory importance in dendritic cell biology.

Experimental Guidance and Technical Tips

• This PE-conjugated rabbit monoclonal antibody targets the extracellular domain (amino acids 45–213) of human CD303/BDCA-2, making it suitable for direct flow cytometric detection of surface receptor expression without permeabilization.
• For optimal FC staining, consider titrating the antibody concentration and including appropriate isotype controls to confirm specificity in your experimental system.
• Since CD303/BDCA-2 is predominantly expressed on plasmacytoid dendritic cells, validate the antibody’s performance using relevant cell lines or primary human samples (e.g., peripheral blood mononuclear cells) with known pDC populations.
• The immunogen corresponds to a recombinant fusion protein; cross-reactivity with other CLEC family members was not specified by the supplier, so orthogonal verification (e.g., via gene knockout or siRNA) may be prudent for critical assays.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutions with comprehensive access to IVD raw materials, including this PE-conjugated anti-CD303/BDCA-2 monoclonal antibody for plasmacytoid dendritic cell research. Beyond individual reagents, we supply validated antibody pairs, optimized monoclonal and polyclonal antibodies, and bulk ancillary reagents to support seamless development workflows. Our sourcing capabilities extend to rare targets, helping you bridge the gap from concept to clinical application.